Biodistribution and Therapeutic Utility of Liposomal Drug Carrier Systems

References

• Los G., Mutsaerts P. H. A., Van der Vijgh W. J. F., Baldew G. S., Van de Graaf P. W., McVie J. G. Direct diffusion of cis- diamminedichloroplatinum (II) in intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989; 49: 3380–84
   PubMed Web of Science ®Google Scholar
• Los G. Experimental basis of intraperitoneal chemotherapy. Thesis, Free University, AmsterdamThe Netherlands 1990
   Google Scholar
• Straubinger R. M., Lopez N. G., Debs R. J., Hong K., Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. 1988; 48: 5237–45
   PubMed Web of Science ®Google Scholar
• Nässander U. K. Liposomes, immunoliposomes and ovarian carcinoma. Thesis, University of Utrecht, The Netherlands 1991
   Google Scholar
• Nässander U. K., Steerenberg P. A., Poppe H., Storm G., Jap P. H. K., Poels L. G., De Jong W. H., Crommelin D. J. A. In vivo targeting of OV-TL3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res. 1992; 52: 646–53
   PubMed Web of Science ®Google Scholar
• Wright S., Huang L. Antibody-directed liposomes as drug-delivery vehicles. Adv. Drug Deliv. Rev. 1989; 3: 343–89
   Google Scholar
• Bagshawe K. D., Springer C. J., Searle F., Antoniw P., Sharma S. K., Melton R. G., Sherwood R. F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 1988; 58: 700–03
   PubMed Web of Science ®Google Scholar
• Haisma H. J., Boven E., Van Muijen M., De Jong J., Van der Vijgh W. J. F., Pinedo H. M. A monoclonal antibody-ß-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 1992; 66: 474–78
   PubMed Web of Science ®Google Scholar
• Vingerhoeds M. H., Haisma H. J., Van Muijen M., Van de Rijt R. B. J., Crommelin D. J. A., Storm G. A new application for liposomes in cancer therapy: immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs, Submitted
   Google Scholar
• Bakker-Woudenberg I. A. J. M., Lokerse A. F., Ten Kate M. T., Storm G. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim. Biophys. Acta 1992; 1138: 318–26
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg I. A. J. M., Lokerse A. F., Ten Kate M. T., Mouton J. W., Woodle M. C., Storm G. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae infected lung tissue. J. Infect. Dis., in press
   Web of Science ®Google Scholar
• Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta 1990; 1029: 91–7
   PubMed Web of Science ®Google Scholar
• Lasic D. D., Martin F. J., Gabizon A., Huang S. K., Papahadjopoulos D. Sterically stabilized liposomes - A hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1991; 1070: 187–92
   PubMed Web of Science ®Google Scholar
• Woodle M. C., Mattay K. K., Newman M. S., Hidayat J. E., Collins L. R., Redemann C., Martin F. J., Papahadjopoulos D. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim. Biophys. Acta 1992; 1105: 193–200
   PubMed Web of Science ®Google Scholar
• Mori A., Klibanov A. L., Torchilin V. P., Huang L. Influence of the steric barrier activity of amphipathic polyethyleneglycol and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 1991; 284: 263–6
   PubMed Web of Science ®Google Scholar
• Maruyama K., Mori A., Bhadra S., Subbiah M. T. R., Huang L. Proteins and peptides bound to long-circulating liposomes. Biochim. Biophys. Acta 1991; 1070: 246–52
   PubMedGoogle Scholar
• Klibanov A. L., Huang L. Long-circulating liposomes: developments and perspectives. J. Liposome Res. 1992; 2: 321–34
   Google Scholar
• Torchilin V. P., Klibanov A. L., Huang L., O'Donnell S., Nossif N. D., Khaw B. A. The FASEB J. 1992; 6: 2716–9
   PubMed Web of Science ®Google Scholar
• Blume G., Cevc G., Crommelin D. J. A., Bakker-Woudenberg I. A. J. M., Kluft C., Storm G. Specific targeting with polyethyleneglycol-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta 1993, in press
   Google Scholar
• Melissen P. M. B., Van Vianen W., Rijsbergen Y., Bakker-Woudenberg I. A. J. M. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamine in treatment of experimental Klebsiella pneumoniae infections. Infect. Immun. 1992; 60: 95–101
   PubMed Web of Science ®Google Scholar
• Emmen F., Storm G. Liposomes in treatment of infectious diseases. Pharm. Weekbl. (Sci. Ed.) 1987; 9: 162–71
   PubMedGoogle Scholar
• Swenson C. E., Popescu M. C., Rinsberg R. S. Preparation and use of liposomes in the treatment of microbial infections. CRC Crit. Rev. Microbiol. 1988; 15(suppl. 1)1–31
   Google Scholar
• Senior J. H. Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit. Rev. Ther. Drug Carrier Syst. 1987; 3: 123–93
   PubMed Web of Science ®Google Scholar
• Woodle M. C., Lasic D. D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992; 1113: 171–99
   PubMed Web of Science ®Google Scholar
• Gabizon A., Price D. C., Huberty J., Bresalier R. S., Papahadjopoulos D. Effect of lipid composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 1990; 50: 6371–8
   PubMed Web of Science ®Google Scholar